Please assess the completion status of the following clinical trial:

Trial Title: Depakote ER in Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bipolar I, II or NOS currently suffering from depression~* Both: both female and male participants are being studied~* Adults 18 years and older of any race~Exclusion Criteria:~* Schizophrenia or schizoaffective disorder and other disorders excluded at the discretion of the investigator's discretion~* Substance dependence within the past 3 months and abuse within the past 2 weeks prior to study.~* Positive screen for psychoactive drugs, stimulants or drugs of abuse (excluding marijuana, as long as dependence and abuse are ruled out according to DSM-IV)~* Significant risk harm to self or others based on history and mental status exam~* Clinically significant or unstable medical condition~* Unstable thyroid pathology and treatment initiated or altered within the past 3 months~* Clinically significant abnormal laboratory test results, vital signs, as judged by the investigators~* Women pregnant or nursing, or WOCBP who do not use adequate contraception or who are judged to be unreliable in their use of contraception~* Subjects who failed (because of inefficacy or adverse effects) an adequate trial of Depakote; eligible patient's may not have received Depakote within 30 days of screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Depakote ER (Type: EXPERIMENTAL): Depakote ER up to 1500 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).